Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

@article{Misale2014BlockadeOE,
  title={Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer},
  author={Sandra Misale and Sabrina Arena and Simona Lamba and Giulia Siravegna and Alice Lallo and Sebastijan Hobor and Mariangela Russo and Michela Buscarino and Luca Lazzari and Andrea Sartore-Bianchi and Katia Bruna Bencardino and Alessio Amatu and Calogero Lauricella and Emanuele Valtorta and Salvatore Siena and Federica Di Nicolantonio and Alberto Bardelli},
  journal={Science Translational Medicine},
  year={2014},
  volume={6},
  pages={224ra26-224ra26}
}
Colorectal cancers (CRCs) that are sensitive to the anti–epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab almost always develop resistance within several months of initiating therapy. We report the emergence of polyclonal KRAS, NRAS, and BRAF mutations in CRC cells with acquired resistance to EGFR blockade. Regardless of the genetic alterations, resistant cells consistently displayed mitogen-activated protein kinase kinase (MEK) and extracellular signal–regulated… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 9 times over the past 90 days. VIEW TWEETS
101 Citations
49 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 101 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

From bench to bedside

  • A. Akinleye, M. Furqan, N. Mukhi, P. Ravella, MEK D. Liu, the inhibitors
  • J. Hematol. Oncol. 6, 27
  • 2013
2 Excerpts

Similar Papers

Loading similar papers…